Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma

In the News: Oncology - February 2017 - Conference Correspondent
Wayne Kuznar

The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.

In this phase 1b dose-escalation study, the overall response rate (ORR) with the triplet therapy was 97%. Patients with high BCL-2 gene expression had greater response rates than patients with low BCL-2 gene expression, said Dr Moreau.

Venetoclax, a BCL-2 inhibitor, has been shown to enhance the activity of bortezomib, an indirect inhibitor of MCL-1, in vitro and in vivo.

“Anti-myeloma activity observed with this new treatment combination of both BCL-2 and MCL-1 supports the ongoing phase 3 clinical trial that is currently enrolling patients, very fast, comparing bortezomib and dexamethasone versus bortezomib and dexamethasone plus venetoclax,” Dr Moreau said.

Venetoclax plus Bortezomib and Dexamethasone

In this dose-escalation study involving 66 patients with previously treated multiple myeloma and adequate organ function, 54 patients received venetoclax, starting at 50 mg daily and increasing to 1200 mg daily, plus bortezomib and dexamethasone; and 12 patients in an expansion cohort received venetoclax 800 mg daily. Of the 66 patients, 39% had disease refractory to previous bortezomib therapy, 53% had disease refractory to previous lenalidomide therapy, and 61% had disease refractory to their last line of treatment.

Approximately 37% of patients were still receiving the combination therapy at the data cutoff date (August 19, 2016). Of the 70% of patients who discontinued treatment, the primary reason (56%) was attributed to disease progression.

The ORR was 67% for all evaluable patients, but reached 90% in patients with disease that was not refractory to bortezomib, including 36% of patients with at least a very good partial response. In patients who were naïve to bortezomib therapy, the ORR was 92%, including 84% with at least a very good partial response.

“Importantly, 31% of the patients that were bortezomib refractory at the time of study entry were able to respond to the treatment combination, and this is a proof of concept that venetoclax is able to overcome bor­tezomib resistance,” Dr Moreau said.

In patients with disease that was not refractory to bortezomib at study entry who received 1 to 3 previous treatments, the ORR was 97%, including 74% with at least a very good partial response.

The median time to disease progression in patients with disease not refractory to bortezomib was 11.3 months versus 1.8 months in patients with refractory disease; the median duration of response was 18 months versus 4 months, respectively.

The median time to disease progression was 11.6 months in patients who received 1 to 3 lines of therapy compared with 4.3 months in patients who received more than 3 lines of therapy; the duration of response was 11 months and 5 months, respectively. In patients with high BCL-2 expression, the ORR was 94% compared with 59% in patients with low BCL-2 expression.

When considered with other data showing high venetoclax activity as monotherapy in patients with a translocation between chromosomes 11 and 14, “we have now some data indicating that maybe we can find some biomarkers that could help in the definition of a subgroup of patients who will benefit most from this combination,” he said.

Related Items
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Lynch Syndrome
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
TOP Web Exclusives published on October 9, 2018 in Multiple Myeloma
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Lynch Syndrome
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
TOP Web Exclusives published on September 11, 2018 in FDA Approvals, News & Updates
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
TOP Web Exclusives published on September 11, 2018 in Side-Effects Management
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
Wayne Kuznar
TOP Web Exclusives published on August 15, 2018 in NCCN News
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Last modified: February 15, 2017